Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 11, 2025Journal of Nuclear Medicine

SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSteven P. RoweBSBrian ShuchMBMark W. Ball

Discussion

Loading...

Member takes

Overview

This guideline outlines how molecular imaging improves risk stratification for renal masses, highlighting CAIX and mitochondrial imaging techniques.

Key Points

  • Molecular imaging improves risk stratification for renal masses, enhancing patient decision-making.
  • Agents targeting CAIX, notably 89Zr-girentuximab, are pivotal in identifying clear cell renal cell carcinoma.
  • Mitochondrial imaging agents, such as 99mTc-sestamibi, differentiate benignant oncocytomas from ccRCC.
  • AI-driven biomarker discovery is set to advance the field of renal mass characterization further.

Cite This Study

Rowe et al. (2025) studied this question.

synapsesocial.com/papers/68ea72339f1bd4df558cec09https://doi.org/10.2967/jnumed.125.271332
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [<sup>68</sup>Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma2024 · 69 citations
  2. 2Diagnostic Accuracy of<sup>99m</sup>Tc-Sestamibi SPECT/CT for Characterization of Solid Renal Masses2022 · 21 citations
  3. 3Clinical Performance of Technetium-99m–Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice2023 · 24 citations
  4. 4Role of 18F-FDG-PET in renal tumors: insights from WHO 2022 classification2025 · 13 citations
  5. 5Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta‐analysis2017 · 106 citations